Pancreatic cancer (PC) is one of the most lethal malignancies, with an overall survival rate below 11%.1 Due to the accumulation of genetic changes, for example, the presence of “driver mutations” in KRAS and TP53 genes (Figure 1), the exocrine component of the pancreas becomes transformed and loses its functions.2,3 This irreversibly affects the physiology of the exocrine pancreas, including the production, storage, and release of digestive enzymes. Here, KRAS is linked to pachyonychia congenita.